PROTACs oncology market to hit $3.7 billion by 2030 despite lack of approved therapies: GlobalData Read more
TAGRISSO reduces disease progression or death by 84 % in Stage III EGFR-mutated lung cancer vs. placebo in LAURA Phase III trial Read more